Skip to main content
John  Maher

Dr John Maher

Consultant and Senior Lecturer in Immunology

Research interests

  • Cancer
  • Immunology

Contact details

Biography

Dr John Maher is a Senior Lecturer within the Comprehensive Cancer Centre. 

    Research

    car mechanics RG thumbnail
    CAR Mechanics Group

    The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.

    experimental-oncology
    Experimental Oncology

    The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

    Project status: Ongoing

    Immunology and Immunotherapy Programme Header
    Cancer Immunology & Immunotherapy

    Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

    Project status: Ongoing

    News

    Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy

    The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...

    clinical trials

    New papers give fresh promise for CAR T-cell cancer immunotherapy

    The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...

    cancer cell cytotoxic T-cells 780x450

    CAR-T therapy modifications provides new promise for cancer immunotherapies

    Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...

    T cell therapies cancer cell 780x450

    King's spin out Leucid Bio wins funding boost for CAR-T therapies

    Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.

    Cancer cells

    Engineering T-cells to selectively target cancer

    Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...

    Researchers Drs James Arnold (Left), Paris Kosti (Middle) and John Maher (right) who developed HypoxiCAR.

    Events

    12JunCorrect DNA (3)780x450

    CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel

    Speaker: John Maher, Division of Cancer Studies, King's College London

    Please note: this event has passed.

    Features

    Transforming cancer care at King's

    King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...

    cancer-cells-blue

    Spotlight

    How King's continues to tackle cancer and support cancer care and research

    Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...

    Cancer cells

      Research

      car mechanics RG thumbnail
      CAR Mechanics Group

      The CAR Mechanics Group originated in 2004 and has sought to develop and translate novel CAR T-cell strategies for the treatment of patients with refractory solid tumours. We have developed several experimental CAR approaches in addition to ancillary technologies that enable improved CAR T-cell expansion and homing to sites of disease. The CAR Mechanics group has advanced one candidate named T4 immunotherapy to Phase 1 clinical trial evaluation with funding from the Jon Moulton Charitable Foundation, Wellcome Trust and the Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust.

      experimental-oncology
      Experimental Oncology

      The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.

      Project status: Ongoing

      Immunology and Immunotherapy Programme Header
      Cancer Immunology & Immunotherapy

      Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.

      Project status: Ongoing

      News

      Leucid Bio gains clinical trial approval for new CAR-T Cell Therapy

      The King’s spin-out will dose its first patients by the end of 2023 in order to test its new CAR-T Cell Therapy, designed for the treatment of adults with...

      clinical trials

      New papers give fresh promise for CAR T-cell cancer immunotherapy

      The two studies, published in Cell Reports Medicine and Froniters in Immunology, have provided new insights into a specific type of CAR T-cell immunotherapy...

      cancer cell cytotoxic T-cells 780x450

      CAR-T therapy modifications provides new promise for cancer immunotherapies

      Researchers from King’s and Leucid Bio have made additional modifications to CAR T-cells receptors, in collaboration with LUMICKS, improving its therapeutic...

      T cell therapies cancer cell 780x450

      King's spin out Leucid Bio wins funding boost for CAR-T therapies

      Researchers developing pioneering cell therapies for hard-to-treat cancers have received a significant funding boost.

      Cancer cells

      Engineering T-cells to selectively target cancer

      Researchers from the Faculty of Life Sciences & Medicine have re-designed the genetic code of cells which can be trained to aggressively attack solid...

      Researchers Drs James Arnold (Left), Paris Kosti (Middle) and John Maher (right) who developed HypoxiCAR.

      Events

      12JunCorrect DNA (3)780x450

      CAR T-cell immunotherapy of solid tumours – learning from the clinic and lab in parallel

      Speaker: John Maher, Division of Cancer Studies, King's College London

      Please note: this event has passed.

      Features

      Transforming cancer care at King's

      King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...

      cancer-cells-blue

      Spotlight

      How King's continues to tackle cancer and support cancer care and research

      Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...

      Cancer cells